Common Leukemia and Lymphoma Medications

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Sick asian senior woman suffering from anorexia,bored with meal,eating less food or discomfort in swallowing,disease of Dysphagia,Old elderly patient having lack of appetite,nutrition and health care | © Satjawat - stock.adobe.com

Ariana Pelosci

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Russ Conroy

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

$The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.$

Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.

Related Content

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Ariana Pelosci

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Russ Conroy

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

$The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.$